Methylethyltryptamine
| Clinical data | |
|---|---|
| Other names | MET; N-Methyl-N-ethyltryptamine; N,N-MET |
| Routes of administration | Oral; Vaporized/inhaled |
| Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a serotonergic psychedelic of the tryptamine family. It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET). The drug acts as an agonist of the serotonin 5-HT2 receptors and to a lesser extent as a serotonin releasing agent. It was encountered as a novel designer drug in Europe in 2014.